MDT

97.73

+2.28%↑

VEEV

296

-1.38%↓

A

141.89

+2.46%↑

HQY

88.52

-1.34%↓

PHR.US

23.12

+1.54%↑

MDT

97.73

+2.28%↑

VEEV

296

-1.38%↓

A

141.89

+2.46%↑

HQY

88.52

-1.34%↓

PHR.US

23.12

+1.54%↑

MDT

97.73

+2.28%↑

VEEV

296

-1.38%↓

A

141.89

+2.46%↑

HQY

88.52

-1.34%↓

PHR.US

23.12

+1.54%↑

MDT

97.73

+2.28%↑

VEEV

296

-1.38%↓

A

141.89

+2.46%↑

HQY

88.52

-1.34%↓

PHR.US

23.12

+1.54%↑

MDT

97.73

+2.28%↑

VEEV

296

-1.38%↓

A

141.89

+2.46%↑

HQY

88.52

-1.34%↓

PHR.US

23.12

+1.54%↑

Search

Emergent BioSolutions Inc

Atvērts

SektorsVeselības aprūpe

9.11 -0.55

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

9.11

Max

9.34

Galvenie mērījumi

By Trading Economics

Ienākumi

-80M

-12M

Pārdošana

-81M

141M

P/E

Sektora vidējais

3.399

35.739

Peļņas marža

-8.517

Darbinieki

900

EBITDA

-131M

1.6M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+28.73% upside

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

154M

477M

Iepriekšējā atvēršanas cena

9.66

Iepriekšējā slēgšanas cena

9.11

Ziņu noskaņojums

By Acuity

7%

93%

5 / 371 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

Emergent BioSolutions Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 2. okt. 23:30 UTC

Karstas akcijas

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2025. g. 2. okt. 21:21 UTC

Peļņas

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

2025. g. 3. okt. 00:00 UTC

Iegādes, apvienošanās, pārņemšana

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2025. g. 2. okt. 23:40 UTC

Tirgus saruna

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2025. g. 2. okt. 23:39 UTC

Tirgus saruna

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2025. g. 2. okt. 23:29 UTC

Iegādes, apvienošanās, pārņemšana

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2025. g. 2. okt. 23:29 UTC

Iegādes, apvienošanās, pārņemšana

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2025. g. 2. okt. 23:29 UTC

Iegādes, apvienošanās, pārņemšana

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2025. g. 2. okt. 23:00 UTC

Tirgus saruna

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2025. g. 2. okt. 22:54 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Scales's JV Buyout Lauded by Bull -- Market Talk

2025. g. 2. okt. 22:54 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 2. okt. 22:46 UTC

Tirgus saruna

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2025. g. 2. okt. 22:46 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 2. okt. 21:17 UTC

Iegādes, apvienošanās, pārņemšana

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2025. g. 2. okt. 20:50 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Energy & Utilities Roundup: Market Talk

2025. g. 2. okt. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 2. okt. 20:49 UTC

Iegādes, apvienošanās, pārņemšana

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2025. g. 2. okt. 20:00 UTC

Iegādes, apvienošanās, pārņemšana

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2025. g. 2. okt. 19:20 UTC

Tirgus saruna

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2025. g. 2. okt. 19:10 UTC

Tirgus saruna

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2025. g. 2. okt. 19:04 UTC

Tirgus saruna

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2025. g. 2. okt. 18:46 UTC

Iegādes, apvienošanās, pārņemšana

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2025. g. 2. okt. 18:46 UTC

Iegādes, apvienošanās, pārņemšana

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2025. g. 2. okt. 18:46 UTC

Iegādes, apvienošanās, pārņemšana

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2025. g. 2. okt. 18:45 UTC

Iegādes, apvienošanās, pārņemšana

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2025. g. 2. okt. 18:45 UTC

Iegādes, apvienošanās, pārņemšana

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2025. g. 2. okt. 18:44 UTC

Iegādes, apvienošanās, pārņemšana

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2025. g. 2. okt. 18:44 UTC

Iegādes, apvienošanās, pārņemšana

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2025. g. 2. okt. 18:44 UTC

Iegādes, apvienošanās, pārņemšana

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2025. g. 2. okt. 18:43 UTC

Iegādes, apvienošanās, pārņemšana

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Salīdzinājums

Cenas izmaiņa

Emergent BioSolutions Inc Prognoze

Cenas mērķis

By TipRanks

28.73% augšup

Prognoze 12 mēnešiem

Vidējais 11.83 USD  28.73%

Augstākais 15 USD

Zemākais 8.5 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Emergent BioSolutions Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

3 ratings

2

Pirkt

1

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

4.95 / N/AAtbalsts un pretestība

Īstermiņā

Bullish Evidence

Vidējā termiņā

Weak Bullish Evidence

Ilgtermiņā

Weak Bearish Evidence

Noskaņojums

By Acuity

5 / 371 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Emergent BioSolutions Inc

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
help-icon Live chat